2012


To access this material please log in or register

Register Authorize
2012/№6

Effect of bisopropol therapy on values of peripheral and central blood pressure, arterial stiffness, diastolic function of the left ventricle and quality of life in patients with hypertension (the KLUCh study)

Orlova Ya. A., Mikhailov G. V., Khezheva F. М., Vitsenia M. V., Ageev F. T.
Federal State Budgetary Institution, “Russian Cardiology Research and Production Complex” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: hyperpiesis, bisoprolol, diastolic dysfunction of the left ventricle, vascular stiffness, quality of life, treatment, central hemodynamics

DOI: 10.18087 / rhj.2012.6.1761

Relevance. Organo- and angioprotective action of drugs are key to the prognosis of treatments efficacy. Central blood pressure is more often offered as a criterion of hypertensive patient treatment effectiveness. Objective of the study was to evaluate the influence of highly selective beta-blocker bisoprolol (Niperten, KRKA, Slovenia) on quality of life in hypertensive patients, indices of peripheral and central blood pressure, LV diastolic function, and study angioprotective action of this drug. Materials and methods. 30 patients (average age 54.5±10.5 years), 10 male and 20 female patients, hypertension of I–II degree and HR≥75 bpm. Rest BP and HR, augmentation index (AI%), systolic (CADs) and pulse pressure (PAP) in aorta (SphygmoCor, Atcor), pulse-wave velocity in carotid-femoral (PWVcf) (SphygmoCor, Atcor) and humero-malleolar (PWVhm) (Vasera VS–1000, Fukuda Denshi) segments, LV diastolic f unction (iE-33, Phillips). Total cholesterol, thyroglobulin, creatinin, blood glucose fasting levels weredetermied. Quality of life (QL) was evaluated with MOS SF 36 Health Survey Version 1.0 questionnaire. All examinations were carried out at baseline and in 3 months of bisoprolol therapy with average daily dose 3.6±1.5 mg. Results. In the course of the therapy, SBP significantly reduced by 10.5 %, DBP by 11.8 %. 93 % of patients achieved the target level of BP. With significant reduction of CADs (from 142.7 to 136.6 mm Hg) and PAP (from 49.7 to 43.3 mm Hg), AI% increased (from 31.5 to 35.2). No negative dynamics of LV diastolic function is revealed. Bisoprolol reduced HR from 81.1 до 68.7 bpm (р<0.001), improved mental and physical components of health, and showed good tolerance and metabolic neutrality. PWVcf (–11.5 %) and PWVhm (–7.5 %) significantly decreased in the first 3 months of treatment. Conclusion. In addition to improvement of QL in hypertensive patients, bisoprolol had positive influence on substitute prognosis markers – PWV, pulse and systolic pressure in aorta.
  1. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbi­dity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet. 2002;359 (9311):995–1003.
  2. Dahlof B, Sever PS, Poulter NR et al.; for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366 (9489):895–906.
  3. Wikstrand J, Warnold I, Tuomilehto J et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension. 1991;17 (4):579–588.
  4. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113 (9):1213–1225.
  5. Roman MJ, Devereux RB, Kizer JR et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50 (1):197–203.
  6. Кашерининов Ю. Р., Шаваров А. А., Виллевальде С. В. и др. Качество жизни у больных гипертонической болезнью на фоне терапии рилменидином в сравнении с атенололом. Арте­ри­альная гипертензия. 2004;10 (4):211–213.
  7. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369 (9557):201–207.
  8. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1‑selectivity of three beta1‑selective beta-blockers. J Clin Pharm Ther. 2003;28 (3):179–186.
  9. Белоусов Ю. Б., Вилковыский Ф. А., Леонова М. В., Маклакова Е. В. Сравнительная эффективность кардиоселективных пролонгированных β-адрено­блокаторов у больных артериальной гипертензией в сочетании с ишемической болезнью сердца. Фарматека. 2003;6 (69):59–64.
  10. Недогода С. В. Бисопролол в лечении артериальной гипертензии. РМЖ. 2011;4:192–194.
  11. Asmar R, Benetos A, Topouchian J et all. Assessment of Arterial Distensibility by Automatic Pulse Wave Velocity Measurement (Validation and Clinical Application Studies). Hypertension. 1995;26 (3):485–490
  12. Милягин В. А., Милягина И. В., Грекова М. В. и др. Новый автоматизированный метод определения скорости распространения пульсовой волны. Функциональная диагностика. 2004;4 (1):33–39.
  13. Yamashina A, Tomiyama H,Takeda K. Validity, reproducibility and clinical significance brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002;25 (3):359–364.
  14. Chen CH, Nevo E, Fetics B et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation. 1997;95 (7):1827–1836.
  15. Овчинников А. Г., Агеев Ф. Т., Мареев В. Ю. Методические аспекты применения Допплер–эхокардиографии в диагностике диастолической дисфункции левого желудочка. Сердечная недостаточность. 2000;1 (2):66–70.
  16. Рыбакова М. К., Алехин М. Н., Митьков В. В. Практическое руководство по ультразвуковой диагностике. Эхокардиография. – М.: Издательский дом Видар-М, 2008. – 512 с.
  17. Ware JE, Sherbourne CD. The MOS 36‑Item short-form health survey. Med Care. 1992;30 (6):473–483.
  18. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993;125 (4):1148–1154.
  19. Rambihar S, Gao P, Teo K et al. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET / TRANSCEND. Circulation. 2010;122 (Suppl 21):A12667.
  20. Julius S, Palatini P, Kjeldsen SE et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109 (5):685–692.
  21. Kawecka-Jaszcz K, Czarnecka D, Klocek M et al. Rilmenidine – its antihypertensive efficacy, safety and impact on quality of life in perimenopausal women with mild to moderate essential hypertension. Blood Press. 2006;15 (1):51–58.
  22. Takase B, Takeishi Y, Hirai T et al. Comparative effects of amlodipine monotherapy and combination therapy with betaxolol on cardiac autonomic nervous activity and health-related quality of life in patients with poorly controlled hypertension. Circ J. 2008;72 (5):764–769.
  23. Кукес В. Г., Остроумова О. Д., Мамаев В. И., и соавт. Эффек­тивность и безопасность различных бета-блокаторов у пациентов с изолированной систолической гипертонией и сопутствующими сахарным диабетом и обструктивными заболеваниями легких. Терапевтический архив, 2003;75 (8):43–47.
  24. Орлова Я. А., Кулев Б. Д., Цыбульская Т. В. и др. Клинические и сосудистые эффекты бетаксолола у больных с артериальной гипертонией. Кардиология. 200646 (11):38–43.
  25. Lithell H, Weiner L, Vessby B, Nordström ML. Effects of small doses of bisoprolol on blood pressure and lipoprotein concentrations in hypertensive patients. Eur J Clin Pharmacol. 1993;44 (1):19–22.
  26. Mengden T., Vettr W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother. 1997;8:55–67.
  27. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364 (9446):1684–1689.
  28. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366 (9496):1545–1553.
  29. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension. 2004;44 (3):305–310.
  30. Asmar RG, London GM, O’Rourke ME, Safar ME, REASON Project Coordinators, Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril / indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38 (4):922–926.
  31. Kampus P, Serg M, Kals J et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57 (6):1122–1128.
  32. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21 (6):663–667.
  33. Kelly R, Daley J, Avolio A, O'Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension. 1989;14 (1):14–21.
  34. Polónia J, Barbosa L, Silva JA, Bertoquini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator pro­perties or with angiotensin receptor blockers. Blood Press Monit. 2010;15 (5):235–239.
  35. Shah NK, Smith SM, Nichols WW et al. Carvedilol reduces aortic wave reflection and improves left ventricular / vascular coupling: a comparison with atenolol (CENTRAL Study). J Clin Hypertens (Greenwich). 2011;13 (12):917–924.
  36. Deary AJ, Schumann AL, Murfet H et al. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond). 2002;103 (5):493–499.
  37. Safar ME, Blacher J, Pannier B et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension. 2002;39 (3):735–738.
  38. Wang KL, Cheng HM, Chuang SY et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens. 2009;27 (3):461–467.
  39. Vlachopoulos C, Aznaouridis K, O'Rourke MF et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31 (15):1865–1871.
  40. Mitchell GF, Hwang SJ, Vasan RS. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121 (4):505–511.
  41. Janner JH, Godtfredsen NS, Ladelund S et al. High aortic augmentation index predicts mortality and cardiovascular events in men from a general population, but not in women. Eur J Prev Cardiol. 2012 May 30
  42. Williams B, Lacy PS. Central haemodynamics and clinical outcomes: going beyond brachial blood pressure? Eur Heart J. 2010;31 (15):1819–1822.
  43. Boutouyrie P, Tropeano AI, Asmar R et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39 (1):10–15.
  44. Laurent S, Boutouyrie P, Asmar R et all. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37 (5):1236–1241.
  45. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28 (12):1462–1536.
  46. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). 2010 г. Доступно на: http://gipertonik.ru / files / recommendation-ag-2010.pdf
  47. Орлова Я. А., Нуралиев Э. Ю., Яровая Е. Б. и др. Снижение артериальной ригидности ассоциировано с благоприятным прогнозом у мужчин с ИБС. Сердце. 2009;8 (5):261–265.
  48. Guerin AP, Blacher J, Pannier B et al. Impact of aortic stiffness attenua­tion on survival of patients in end-stage renal failure. Circulation. 2001;103 (7):987–992.
  49. Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol. 1991;68 (1):61–64.
  50. Kahonen M, Ylitalo R, Koobi T et al. Influences of nonselective, beta (1) – selective and vasodilatory beta (1) – selective beta-blockers on arterial pulse wave velocity in normotensive subjects. Gen Pharmacol. 2000 Oct;35 (4):219–224.
  51. Mackenzie IS, McEniery CM, Dhakam Z et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009;54 (2):409–413.
  52. Caramelli B, dos Santos RD, Abensur H et al. Beta-blocker infusion did not improve left ventricular diastolic function in myocardial infarction: a Doppler echocardiography and cardiac catheterization study. Clin Cardiol. 1993;16 (11):809–814.
  53. Агеев Ф. Т., Мареев В. Ю., Лопатин Ю. М., Беленков Ю. Н. Роль различных клинических, гемодинамических и нейрогуморальных факторов в определении тяжести хронической сердечной недостаточности. Кардиология 1995;35 (11):4–12.
  54. Clements IP, Miller WL. Effect of metoprolol on rest and exercise left ventricular systolic and diastolic function in idiopathic dilated cardiomyopathy. Am Heart J. 2001;141 (2):259.
Orlova Ya. A., Mikhailov G. V., Khezheva F. М. et al. Effect of bisopropol therapy on values of peripheral and central blood pressure, arterial stiffness, diastolic function of the left ventricle and quality of life in patients with hypertension (the KLUCh study). Russian Heart Journal. 2012;11(6):342-350.

To access this material please log in or register

Register Authorize
Ru En